The AirAvant Medical team is looking forward to sharing their poster findings with the attendees at the SLEEP 2019 conference in San Antonio on June 8-12. The opportunity to engage with industry experts, doctors, and providers is sure to generate even more clinical interest in using the Bongo® Rx, an expiratory positive airway pressure (EPAP) device for patients with mild to moderate sleep apnea. The results of the study and the performance of the device offer clinicians valuable insights on a viable therapeutic option for their patients. The Bongo® Rx will be on display at the AirAvant Medical Booth # 832 and their team of experts will be on hand to answer any questions about the product, its clinical efficacy, and its availability.
“Long-term CPAP compliance continues to range from 30-70%, but we believe the Bongo® Rx can help level the playing field for those with mild to moderate sleep apnea,” said Ron Richard. “The aim of the study was to evaluate the efficacy and safety of the Bongo® Rx. Not only can this product work for non-compliant patients, it can be a great supplemental option for compliant patients that travel.”
The Bongo® Rx is an FDA-cleared, prescription device for treating mild to moderate obstructive sleep apnea (OSA). With its soft nasal seals, it is easy to use and requires no power. The Bongo® Rx is reusable and is perfect for traveling patients that want to use it anytime, anywhere. The Bongo® Rx website, www.AirAvant.com, includes new educational videos and materials for both the patient and the provider. Doctors, Dentists, and DMEs can email us at info@AirAvant.com or call 888.925.2526 to request information or to place orders.
Source: AirAvant Medical